iShares Biotechnology ETF (NASDAQ:IBB) Sets New 52-Week High – What’s Next?

iShares Biotechnology ETF (NASDAQ:IBB) shares hit a new 52-week high during trading on Monday . The stock traded as high as $169.30 and last traded at $169.4550, with a volume of 310193 shares traded. The stock had previously closed at $167.52.

iShares Biotechnology ETF Stock Performance

The stock has a 50-day moving average price of $153.36 and a 200-day moving average price of $138.62.

iShares Biotechnology ETF Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 19th. Stockholders of record on Tuesday, September 16th were paid a $0.0828 dividend. This represents a $0.33 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date of this dividend was Tuesday, September 16th.

Institutional Trading of iShares Biotechnology ETF

A number of institutional investors have recently bought and sold shares of IBB. Citigroup Inc. raised its position in shares of iShares Biotechnology ETF by 88.5% in the 1st quarter. Citigroup Inc. now owns 3,208,144 shares of the financial services provider’s stock worth $410,322,000 after acquiring an additional 1,505,976 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of iShares Biotechnology ETF by 313.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,915,395 shares of the financial services provider’s stock valued at $276,526,000 after purchasing an additional 1,451,820 shares in the last quarter. Jefferies Financial Group Inc. acquired a new stake in iShares Biotechnology ETF during the third quarter worth approximately $65,083,000. JPMorgan Chase & Co. increased its holdings in iShares Biotechnology ETF by 74.2% in the second quarter. JPMorgan Chase & Co. now owns 833,196 shares of the financial services provider’s stock worth $105,408,000 after purchasing an additional 355,000 shares in the last quarter. Finally, Employees Retirement System of Texas acquired a new position in iShares Biotechnology ETF in the second quarter valued at approximately $25,049,000. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.